Список литературы

1. Swerdlow SH, Campo E, Harris NL, et al. eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edition). Lyon: IARC Press, 2008: 285 - 288.

2. Parrilla Castellar ER, Jaffe ES, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014; 124(9): 1473 - 80.

3. Chan JKC, Quintanilla-Martinez L, Ferry JA, et al. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al. eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th edition). Lyon: IARC Press, 2008: 285 - 288.

4. Mansoor A, Pittaluga S, Beck PL, et al. NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood 2011; 117: 1447 - 1452.

5. Tanaka T, Megahed N, Takata K, et al. A case of lymphomatoid gastropathy: An indolent CD56-positive atypical gastric lymphoid proliferation, mimicking aggressive NK/T cell lymphomas. Pathol. Res. Pract. 2011; 207: 786 - 789.

6. Sieniawski M, Angamuthu N, Boyd K, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010; 115(18): 3664 - 3670.

7. Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients ina single center. J Clin Oncol. 2000; 18(4): 795 - 803.

8. Green PH, Cellier C Celiac disease. N Engl J Med. 2007; 357(17): 1731 - 1743.

9. Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathyassociated T-cell lymphoma. French Coeliac Disease Study Group. Lancet. 2000; 356(9225): 203 - 208.

10. Al-Toma A, Verbeek WH, Hadithi M, et al. Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut. 2007; 56(10): 1373 - 1378.

11. Daum S, Cellier C, Mulder CJ. Refractory coeliac disease. Best Pract Res Clin Gastroenterol. 2005; 19(3): 413 - 424.

12. Deleeuw RJ, Zettl A, Klinker E, et al. Whole genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology. 2007; 132(5): 1902 - 1911.

13. Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood. 2011; 118: 148 - 155.

14. Dube C, Rostom A, Sy R, et al. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology. 2005; 128(4 suppl 1): S57 - S67.

15. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003; 163(3): 286 - 292.

16. Greco L, Romino R, Coto I, et al. The first large population based twin study of coeliac disease. Gut. 2002; 50: 624 - 628.

17. Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features J Gastrointest Oncol. 2012; 3(3): 209 - 225.

18. Musshoff K. Clinical staging classification of non-Hodgkin's lymphomas. Strahlentherapie. 1977; 153(4): 218 - 221.

19. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14): 987 - 994.

20. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004; 103(7): 2474 - 9.

21. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Orthod. 2006; 24(16): 2472 - 9.

22. Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphomas). Br J Haematol. 2011; 153(4): 451 - 85.

23. Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high grade B-cell lymphomas. Leuk Lymphoma. 1996; 24(1-2): 121 - 9.

24. Karakas T, Bergmann L, Stutte HJ, et al. Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high grade B-cell lymphomas. Leuk Lymphoma. 1996; 24(1-2): 121 - 9.

25. Kim SJ, Kim WS. Treatment of localized extranodal NK/T-cell lymphoma, nasal type. Int J Hematol. 2010; 92(5): 690 - 696.

26. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys. 2002; 54(1): 182 - 190.

27. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and HE nasal natural killer/T-cell lymphoma. J Clin Oncol. 2006; 24(1): 181 - 189.

28. Wang ZY, Li YX, Wang WH, et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood. 2009; 114(23): 4771 - 4776.

29. Yang Y, Zhu Y, Cao J-Z, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood. 2015; 126(12): 1424 - 1432.

30. Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120(15): 2973 - 2980.

31. Egan LJ, Walsh SV, Stevens FM, et al. Celiac-associated lymphoma: a single institution experience of 30 cases in the combination chemotherapy era. J Clin Gastroenterol. 1995; 21(2): 123 - 129.

32. Novakovic BJ, Novakovic S, Frkovic-Grazio S. A single-center report on clinical features and treatment response in patients with intestinal T cell non-Hodgkin's lymphomas. Oncol Rep. 2006; 16(1): 191 - 195.

33. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal Non-Hodgkin's Lymphoma. J Clin Oncol. 2003; 21(14): 2740 - 2746.

34. Wohrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004; 15(11): 1680 - 1683.

35. Sabatino A, Biagi F, Gobbi PG, Corazza GR. How I treat enteropathy-associated T-cell lymphoma. Blood. 2012; 119: 2458 - 2468.

36. Tse E., Gill H., Kim S.J. et al. Type II enteropathy-associated T-cell lymphoma: multicenter analysis from the Asia Lymphoma study Group. Am J Hematol. 2012; 87(7): 663 - 8.

37. Falchook GS, Vega NH, DangF, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 20: 1080 - 1085.

38. Jantunen E, et al. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT. Blood. 2013; 121: 2529 - 2532

39. Rashidi A, Cashen AF. Outcomes of allogeneic stemm cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer J. 2015; 5: e318.

40. Hopfinger G, Busch R, Pflug N, et al. Sequental immunochemotherapy of fludarabine, mitoxantron, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer. 2013; 199: 2258 - 2267.

41. Herbaux C, Genet P, Bouabdallah K, et al. Bendamustine is effective in T-cell prolymphocytic leukaemia. British Journal of Haematology. 2015; 168, 902 - 919.